Friday, 19 July 2024


Japan approves first post-transplant anti- cytomegalovirus infection treatment

24 June 2024 | News

Cytomegalovirus is one of the most common and serious post-transplant infections

Takeda Pharma has announced that LIVTENCITY (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies. LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.

The approval is primarily based on the results of the Phase 3 SOLSTICE trial, which evaluated the safety and efficacy of LIVTENCITY versus alternative antiviral treatments for patients with CMV infection/disease refractory to prior therapies who underwent hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT), and the Japanese Phase 3 open-label study in patients with CMV infection, including those with refractory CMV infection who underwent HSCT or SOT.

LIVTENCITY (maribavir), an orally administered (tablet) anti-CMV compound, is the first and only antiviral agent that targets and inhibits the CMV-specific UL97 protein kinase and thus its natural substrates. As of June 2024, LIVTENCITY is approved in more than 30 countries for post-transplant CMV refractory to prior therapies, including such major markets as Japan, the United States, Canada, Australia, the European Union and China.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account